4503   Astellas Pharma Inc.

04/25/2024 15:00	Presentation Material for Information Meeting (FY2023)
04/25/2024 15:00	Supplementary Documents (FY2023)
04/25/2024 15:00	Financial Results (FY2023)
04/25/2024 15:00	Change of Directors
04/25/2024 15:00	Change in Definition of Core Basis in Financial Results
04/22/2024 08:30	Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction Against the Generic Versions of Myrbetriq
04/12/2024 16:00	Notice Regarding Impairment Loss for intangible assets, Change in fair value of contingent consideration, and Revision of Financial Forecasts for FY23
03/25/2024 08:30	Astellas Receives Positive CHMP Opinion for XTANDITM in Additional Recurrent Early Prostate Cancer Treatment Setting
02/21/2024 08:30	Presentation Material for Sustainability Meeting
02/05/2024 15:00	Financial Results (Q3/FY2023)
02/05/2024 15:00	Supplementary Documents (Q3/FY2023)
02/05/2024 15:00	Presentation Material for Information Meeting (Q3/FY2023)
01/31/2024 11:00	Astellas Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First Line Treatment of Advanced Bladder Cancer
01/29/2024 08:30	EMA Validates Type II Variation Application for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer
01/09/2024 08:30	Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.
12/26/2023 11:00	Corporate Governance Report
12/22/2023 08:30	Astellas Completes Acquisition of Propella Therapeutics
12/18/2023 08:30	PADCEV with KEYTRUDA Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
12/01/2023 08:30	FDA Grants Priority Review for sBLA of PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer
11/17/2023 15:00	Pfizer and Astellas' XTANDI Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
11/16/2023 08:30	Astellas to Acquire Propella Therapeutics
11/01/2023 15:00	Financial Results (Q2/FY2023)
11/01/2023 15:00	Supplementary Documents (Q2/FY2023)
11/01/2023 15:00	Presentation Material for Information Meeting (Q2/FY2023)
10/16/2023 08:30	Astellas Receives Positive CHMP Opinion for VEOZA(fezolinetant)
09/22/2023 18:00	PADCEV and KEYTRUDA Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer
09/19/2023 08:00	Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atroph
09/13/2023 08:30	European Medicines Agency Validates Type II Variation for Astellas' XTANDI for Treatment of Non Metastatic Hormone-Sensitive Prostate Cancer
08/25/2023 15:00	Notice Regarding Issuance of Unsecured Bonds
08/24/2023 08:30	FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
08/07/2023 08:00	Iveric Bio Receives U.S. FDA Approval for IZERVAY (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
08/01/2023 15:00	Transforming Astellas Japan Commercial business to deliver growth for the future
08/01/2023 15:00	Presentation Material for Information Meeting (Q1/FY2023)
08/01/2023 15:00	Supplementary Documents (Q1/FY2023)
08/01/2023 15:00	Financial Results (Q1/FY2023)
07/12/2023 08:00	Astellas Completes Acquisition of Iveric Bio
07/06/2023 15:00	Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics Licese Application
06/12/2023 08:30	Astellas Confirms Unfavorable District Court Decision in Myrbetriq U.S. Patent Trial
06/09/2023 13:00	Astellas Submits New Drug Apprication for Zolbetuximab in Japan
05/30/2023 08:00	Notice of Convocation of the 18th Term Annual Shareholders Meeting
05/17/2023 16:05	Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme for the Domestic and Global Astellas Group Executives
05/17/2023 16:00	Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme
05/11/2023 08:30	Astellas Confirms Final Federal Circuit Decision in LEXISCAN 0.4 mg/mL U.S. Patent Appeal